GOSS
Price
$0.98
Change
-$0.01 (-1.01%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
222.34M
40 days until earnings call
MEIP
Price
$2.15
Change
-$0.00 (-0.00%)
Updated
Apr 2 closing price
Capitalization
14.33M
Ad is loading...

GOSS vs MEIP

Header iconGOSS vs MEIP Comparison
Open Charts GOSS vs MEIPBanner chart's image
Gossamer Bio
Price$0.98
Change-$0.01 (-1.01%)
Volume$10.46K
Capitalization222.34M
MEI Pharma
Price$2.15
Change-$0.00 (-0.00%)
Volume$9.33K
Capitalization14.33M
GOSS vs MEIP Comparison Chart
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. MEIP commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and MEIP is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (GOSS: $0.99 vs. MEIP: $2.15)
Brand notoriety: GOSS and MEIP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 154% vs. MEIP: 121%
Market capitalization -- GOSS: $222.34M vs. MEIP: $14.33M
GOSS [@Biotechnology] is valued at $222.34M. MEIP’s [@Biotechnology] market capitalization is $14.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileMEIP’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • MEIP’s FA Score: 0 green, 5 red.
According to our system of comparison, MEIP is a better buy in the long-term than GOSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 5 TA indicator(s) are bullish while MEIP’s TA Score has 4 bullish TA indicator(s).

  • GOSS’s TA Score: 5 bullish, 4 bearish.
  • MEIP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than MEIP.

Price Growth

GOSS (@Biotechnology) experienced а -22.32% price change this week, while MEIP (@Biotechnology) price change was -8.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.27%. For the same industry, the average monthly price growth was -7.37%, and the average quarterly price growth was -12.08%.

Reported Earning Dates

GOSS is expected to report earnings on May 13, 2025.

MEIP is expected to report earnings on Aug 31, 2023.

Industries' Descriptions

@Biotechnology (-5.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GOSS($222M) has a higher market cap than MEIP($14.3M). GOSS YTD gains are higher at: 8.169 vs. MEIP (-12.602). MEIP has higher annual earnings (EBITDA): -29.13M vs. GOSS (-39.97M). GOSS has more cash in the bank: 295M vs. MEIP (23.7M). MEIP has less debt than GOSS: MEIP (11.7M) vs GOSS (203M). GOSS has higher revenues than MEIP: GOSS (115M) vs MEIP (0).
GOSSMEIPGOSS / MEIP
Capitalization222M14.3M1,552%
EBITDA-39.97M-29.13M137%
Gain YTD8.169-12.602-65%
P/E RatioN/A1.09-
Revenue115M0-
Total Cash295M23.7M1,245%
Total Debt203M11.7M1,735%
FUNDAMENTALS RATINGS
GOSS vs MEIP: Fundamental Ratings
GOSS
MEIP
OUTLOOK RATING
1..100
6712
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
5483
P/E GROWTH RATING
1..100
10037
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEIP's Valuation (61) in the Pharmaceuticals Other industry is in the same range as GOSS (65) in the Pharmaceuticals Major industry. This means that MEIP’s stock grew similarly to GOSS’s over the last 12 months.

MEIP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that MEIP’s stock grew similarly to GOSS’s over the last 12 months.

MEIP's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as GOSS (99) in the Pharmaceuticals Major industry. This means that MEIP’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as MEIP (83) in the Pharmaceuticals Other industry. This means that GOSS’s stock grew similarly to MEIP’s over the last 12 months.

MEIP's P/E Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that MEIP’s stock grew somewhat faster than GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSMEIP
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 22 days ago
84%
Bullish Trend 6 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NSEPX20.18N/A
N/A
Columbia Select Large Cap Equity Inst
ECCPX43.66N/A
N/A
Eaton Vance Tax-Managed Multi-Cap Gr C
JBATX27.93N/A
N/A
JHancock Balanced R2
WSCGX30.83N/A
N/A
Allspring Small Company Growth Inst
CGLIX16.11N/A
N/A
Calvert Global Equity Fund Class I

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with MEIP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then MEIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
-1.59%
MEIP - GOSS
46%
Loosely correlated
N/A
CGEM - GOSS
45%
Loosely correlated
+4.27%
SYRE - GOSS
41%
Loosely correlated
+1.27%
APVO - GOSS
41%
Loosely correlated
+38.26%
VIR - GOSS
41%
Loosely correlated
+4.85%
More

MEIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEIP has been loosely correlated with GOSS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MEIP jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEIP
1D Price
Change %
MEIP100%
N/A
GOSS - MEIP
45%
Loosely correlated
-1.59%
FBIO - MEIP
28%
Poorly correlated
+4.55%
AXON - MEIP
28%
Poorly correlated
+3.18%
DNLI - MEIP
26%
Poorly correlated
+11.80%
GLUE - MEIP
25%
Poorly correlated
-0.45%
More